Humanitas Global Health has launched with plans to commercialize artificial intelligence technologies developed at Louisiana State University (LSU), targeting applications in drug discovery, medication safety and clinical decision support. The mission-driven company has licensed LSU’s DeepDrug technologies, which combine AI, molecular design and predictive modeling to support the identification and assessment of potential drug candidates. Humanitas aims to translate the research into practical tools for pharmaceutical development while emphasizing transparency, traceability and experimentally testable results.

The company announced its launch during the American Association of Pharmaceutical Scientists’ PharmSci 360 conference in New Orleans this week. DeepDrug was developed by an LSU research team led by Professor Supratik Mukhopadhyay. Under the licensing agreement, Humanitas plans to apply the technology to pharmaceutical research, using explainable AI to prioritize drug candidates and connect computational predictions with physicochemical properties and potential pharmacological and toxicological mechanisms. The approach is intended to help researchers identify promising compounds and focus laboratory and preclinical testing.

Humanitas is also developing InteractIQ, an AI platform designed to assess patients’ medication regimens and identify potentially harmful drug-drug interactions. The system is undergoing retrospective validation using real-world electronic health record data from LCMC Health. The company aims to identify clinically significant risks while reducing unnecessary alerts that can contribute to alert fatigue among healthcare professionals.

Chris Galliano, Founder and CEO of Humanitas Global Health, says the company intends to connect drug discovery and medication safety through AI systems whose predictions can be evaluated and whose outputs can be traced to supporting evidence. He emphasized that the goal extends beyond generating predictions to ensuring they can be tested and applied in ways that benefit patients.

The company is also introducing its concept of “Ethical Intelligence,” an approach that incorporates ethical principles and respect for human dignity into AI system design. According to Humanitas, the framework emphasizes explainable reasoning, verifiable evidence and clear acknowledgment of uncertainty, while maintaining human oversight of consequential decisions.

James Dalton, PhD, Chancellor of Louisiana State University, says the DeepDrug licensing agreement creates an opportunity to translate university research into applications intended to benefit patients.

Humanitas plans to pursue applications across the pharmaceutical development and healthcare continuum, from evaluating potential medicines to helping clinicians manage medication-related risks. The technologies will need to demonstrate their performance through rigorous validation before their clinical utility can be established, particularly in settings where inaccurate predictions could affect treatment decisions. By combining computational drug discovery with medication safety tools, Humanitas is positioning explainable and auditable AI as a means of supporting more informed decisions in research and clinical care.

For more information, visit www.humanitasglobalhealth.com.